{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=8&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Cincinnati",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 10545,
    "total_pages": 1055,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=9&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=7&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T05:07:50.443Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07128615",
      "title": "A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza A"
      ],
      "interventions": [
        {
          "name": "AZD4117",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD5315",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 405,
      "start_date": "2025-09-04",
      "completion_date": "2026-12-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 14,
      "location_summary": "Long Beach, California • Rolling Hills Estates, California • Miami Lakes, Florida + 11 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07128615"
    },
    {
      "nct_id": "NCT02819297",
      "title": "BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Constipation",
        "Chronic Idiopathic Constipation",
        "CIC"
      ],
      "interventions": [
        {
          "name": "BLI400 Laxative",
          "type": "DRUG"
        },
        {
          "name": "BLI400 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Braintree Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1020,
      "start_date": "2016-06",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819297"
    },
    {
      "nct_id": "NCT01829113",
      "title": "Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Squamous Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "OGX-427",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2013-07",
      "completion_date": "2017-04-19",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 16,
      "location_summary": "Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 13 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01829113"
    },
    {
      "nct_id": "NCT05301933",
      "title": "Telehealth BPT in DBP Practice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Behavioral Parent Training (BPT)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Years to 11 Years"
      },
      "enrollment_count": 13,
      "start_date": "2022-07-01",
      "completion_date": "2023-09-11",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 3,
      "location_summary": "New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05301933"
    },
    {
      "nct_id": "NCT00379847",
      "title": "An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyponatremia"
      ],
      "interventions": [
        {
          "name": "conivaptan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 251,
      "start_date": "2004-02",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 7,
      "location_summary": "Tuscon, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Petoskey",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00379847"
    },
    {
      "nct_id": "NCT05714085",
      "title": "Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure",
        "Left Ventricular Systolic Dysfunction"
      ],
      "interventions": [
        {
          "name": "Vericiguat tablet",
          "type": "DRUG"
        },
        {
          "name": "Vericiguat suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "29 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "29 Days to 17 Years"
      },
      "enrollment_count": 342,
      "start_date": "2023-05-31",
      "completion_date": "2032-05-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05714085"
    },
    {
      "nct_id": "NCT00099125",
      "title": "Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2004-11",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-01-24",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 118,
      "location_summary": "Phoenix, Arizona • Burbank, California • Fresno, California + 91 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099125"
    },
    {
      "nct_id": "NCT05257408",
      "title": "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Neoplasm",
        "Fallopian Tube Neoplasms",
        "Peritoneal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Relacorilant 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel 80 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel 100 mg/m^2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 381,
      "start_date": "2022-06-29",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05257408"
    },
    {
      "nct_id": "NCT01522976",
      "title": "Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia",
        "Chronic Myelomonocytic Leukemia-1",
        "Chronic Myelomonocytic Leukemia-2",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Myelodysplastic Syndrome With Excess Blasts-1",
        "Myelodysplastic Syndrome/Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2012-03-01",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 280,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522976"
    },
    {
      "nct_id": "NCT05157191",
      "title": "Safety of Pediatric COVID-19 Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pain",
        "Injection Site Reaction",
        "Adverse Drug Event"
      ],
      "interventions": [
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "5 Years to 15 Years"
      },
      "enrollment_count": 299,
      "start_date": "2022-04-06",
      "completion_date": "2023-10-27",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-31T05:07:50.443Z",
      "location_count": 5,
      "location_summary": "Oakland, California • Atlanta, Georgia • New York, New York + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05157191"
    }
  ]
}